Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists

RS Westphal and E Sanders-Bush

Department of Pharmacology, School of Medicine, Vanderbilt University, Nashville, Tennessee 37232.

Expression of the 5-hydroxytryptamine type 2C (5-HT 2C) receptor in NIH/3T3 fibroblasts results in agonist-independent 5-HT2C receptor activation. Some 5-HT2c receptor antagonists decrease this activation and are termed inverse agonists. The present study uses this system to evaluate functional and receptor binding properties of other 5-HT2C receptor antagonists. A number of inverse agonists, including clozapine, and a neutral antagonist (methysergide) were identified in a functional assay. Guanine nucleotides increased the affinity of a radiolabeled inverse agonist ([3H]mesulergine), suggesting that inverse agonists bind the G protein-uncoupled form of the 5-HT2C receptor with high affinity. Competition binding was performed using conditions that separately labeled the G protein-coupled and -uncoupled forms of the receptor. These studies demonstrated that inverse agonists bound the uncoupled form of the 5-HT2C receptor with higher affinity, compared with the G protein-coupled form. Agonists, on the other hand, had higher affinity for the coupled form whereas neutral antagonists had equal affinity for both forms of the receptor. Thus, 5-HT2C receptor neutral antagonists exhibited functional and receptor binding properties consistent with those of classical receptor antagonists. However, 5-HT2C receptor inverse agonists displayed functional and receptor binding properties that were opposite those of agonists.

Volume 46, Issue 5, pp. 937-942, 11/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. P. Fitzsimons, F. Monczor, N. Fernandez, C. Shayo, and C. Davio Mepyramine, a Histamine H1 Receptor Inverse Agonist, Binds Preferentially to a G Protein-coupled Form of the Receptor and Sequesters G Protein J. Biol. Chem., August 13, 2004; 279(33): 34431 - 34439. [Abstract] [Full Text] [PDF]

				E. R. Benjamin, S. L. Haftl, D. N. Xanthos, G. Crumley, M. Hachicha, and K. J. Valenzano A Miniaturized Column Chromatography Method for Measuring Receptor-Mediated Inositol Phosphate Accumulation J Biomol Screen, June 1, 2004; 9(4): 343 - 353. [Abstract] [PDF]

				T. Kenakin Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11. [Abstract] [Full Text] [PDF]

				J. A. Harvey Role of the Serotonin 5-HT2A Receptor in Learning Learn. Mem., September 1, 2003; 10(5): 355 - 362. [Abstract] [Full Text] [PDF]

				F. Monczor, N. Fernandez, B. L. Legnazzi, M. E. Riveiro, A. Baldi, C. Shayo, and C. Davio Tiotidine, a Histamine H2 Receptor Inverse Agonist That Binds with High Affinity to an Inactive G-Protein--Coupled Form of the Receptor. Experimental Support for the Cubic Ternary Complex Model Mol. Pharmacol., August 1, 2003; 64(2): 512 - 520. [Abstract] [Full Text] [PDF]

				M. Azzi, G. Pineyro, S. Pontier, S. Parent, H. Ansanay, and M. Bouvier Allosteric Effects of G Protein Overexpression on the Binding of beta -Adrenergic Ligands with Distinct Inverse Efficacies Mol. Pharmacol., November 1, 2001; 60(5): 999 - 1007. [Abstract] [Full Text] [PDF]

				L. Rauser, J. E. Savage, H. Y. Meltzer, and B. L. Roth Inverse Agonist Actions of Typical and Atypical Antipsychotic Drugs at the Human 5-Hydroxytryptamine2C Receptor J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 83 - 89. [Abstract] [Full Text] [PDF]

				K. Herrick-Davis, E. Grinde, and M. Teitler Inverse Agonist Activity of Atypical Antipsychotic Drugs at Human 5-Hydroxytryptamine2C Receptors J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 226 - 232. [Abstract] [Full Text]

				J. A. Durr, J. Hensen, T. Ehnis, and M. S. Blankenship Chlorpropamide upregulates antidiuretic hormone receptors and unmasks constitutive receptor signaling Am J Physiol Renal Physiol, May 1, 2000; 278(5): F799 - F808. [Abstract] [Full Text] [PDF]

				P. J. Pauwels, S. Tardif, T. Wurch, and F. C. Colpaert Facilitation of Constitutive alpha 2A-Adrenoceptor Activity by Both Single Amino Acid Mutation (Thr373Lys) and Galpha o Protein Coexpression: Evidence for Inverse Agonism J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 654 - 663. [Abstract] [Full Text]

				G. Cai, H. Gurdal, C. Smith, H.-Y. Wang, and E. Friedman Inverse Agonist Properties of Dopaminergic Antagonists at the D1A Dopamine Receptor: Uncoupling of the D1A Dopamine Receptor from Gs Protein Mol. Pharmacol., November 1, 1999; 56(5): 989 - 996. [Abstract] [Full Text]

				F. Roka, L. Brydon, M. Waldhoer, A. D. Strosberg, M. Freissmuth, R. Jockers, and C. Nanoff Tight Association of the Human Mel1a-Melatonin Receptor and Gi: Precoupling and Constitutive Activity Mol. Pharmacol., November 1, 1999; 56(5): 1014 - 1024. [Abstract] [Full Text]

				C. M. Niswender, S. C. Copeland, K. Herrick-Davis, R. B. Emeson, and E. Sanders-Bush RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity J. Biol. Chem., April 2, 1999; 274(14): 9472 - 9478. [Abstract] [Full Text] [PDF]

				E. Aberdam, C. Bertolotto, E. V. Sviderskaya, V. de Thillot, T. J. Hemesath, D. E. Fisher, D. C. Bennett, J.-P. Ortonne, and R. Ballotti Involvement of Microphthalmia in the Inhibition of Melanocyte Lineage Differentiation and of Melanogenesis by Agouti Signal Protein J. Biol. Chem., July 31, 1998; 273(31): 19560 - 19565. [Abstract] [Full Text] [PDF]

				M. Bouaboula, S. Perrachon, L. Milligan, X. Canat, M. Rinaldi-Carmona, M. Portier, F. Barth, B. Calandra, F. Pecceu, J. Lupker, et al. A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1. EVIDENCE FOR A NEW MODEL OF RECEPTOR/LIGAND INTERACTIONS J. Biol. Chem., August 29, 1997; 272(35): 22330 - 22339. [Abstract] [Full Text] [PDF]